Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

product recall

- PMLiVE

FDA approves Teva’s Huntington’s disease drug at second attempt

Austedo will treat fatal degenerative disorder chorea

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

- PMLiVE

FDA sets August review date for Teva’s movement disorder drug

Could be first approved treatment for tardive dyskinesia

- PMLiVE

Dr Reddy’s brings its generics portfolio to France

Continues the European roll-out of its oncology and anti-infective products

- PMLiVE

GSK’s Witty ends on a high, but warns 2017 looking ‘uncertain’

Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

- PMLiVE

Change at the top at Teva as Vigodman departs

CEO replaced ad interim by chairman Yitzhak Peterburg as search begins

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

Market access in Europe: balancing access and affordability

European governments continue to pursue national agendas for market access, while also exploring opportunities to work together to achieve lower prices for new drugs

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

- PMLiVE

Teva hit with largest-ever fine under US anti-corruption act

Company to pay $519m after promoting Copaxone in Russia, Ukraine and Mexico

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links